Albert D. Friesen | |
|---|---|
 | |
| Born | May 19, 1947 |
| Occupation(s) | President and CEO |
| Employer | Winnipeg Rh Institute |
| Known for | WinRho |
Albert David "Bert" Friesen, OC OM (born May 19, 1947) is a Canadian biotechnologist involved in biotechnology innovation. [1] His biotechnology career began as the first full-time employee of the Winnipeg Rh Institute, where he later became president and CEO, and led the development of WinRho, one of Canada's first successful biotech products. [2]
Albert Friesen went to the University of Manitoba and earned a Ph.D. in protein chemistry. [3]
In 1987, Dr. Friesen was a founder and the company’s first board of directors Chairman at the Industrial Biotechnology Association of Canada (IBAC) which is now known as BIOTECanada. [4]
In 1997, Friesen founded Medicure, which sells a large number of cardiovascular products. In 2020, Medicure purchased Marley Drug and the company can now sell medications directly to patients. [4]
From 2014-2017, Friesen was chair on the International board of MEDA (Mennonite Economic Development Associates). [4]
In March 2023, Dr. Friesen was awarded Outstanding Leadership in Bioscience of the Year at the Annual Bioscience Association Manitoba (BAM) gala. [4]
He was made an Member of the Order of Canada in 2025. [5]
   | This article about a Canadian scientist is a stub. You can help Wikipedia by expanding it. |
 | This biotechnology article is a stub. You can help Wikipedia by expanding it. |